Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › rucaparib

rucaparib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of rucaparib

20 trials tracked of rucaparib: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 409 citations.

20Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 4 Phase 2 12 Phase 1 3 Other / NA 1
  1. Phase 3 A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Completed · 409 cited
  2. Phase 3 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Completed · 143 cited
  3. Phase 3 Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) Completed · 127 cited
  4. Phase 3 CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Completed
  5. Phase 2 PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers Completed
  6. Phase 2 Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy Completed
Show 14 more trials
  1. Phase 2 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Completed
  2. Phase 2 A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Completed
  3. Phase 2 A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Completed
  4. Phase 2 A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Completed
  5. Phase 2 Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Completed
  6. Phase 2 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Completed
  7. Phase 2 The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) Completed
  8. Phase 2 Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer Completed
  9. Phase 2 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Completed
  10. Phase 2 An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer Completed
  11. Phase 1 A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Completed
  12. Phase 1 A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy Completed
  13. Phase 1 Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) Completed
  14. N/A Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase II trial of rucaparib maintenance in metastatic endometrial cancer completes follow-up
Drug Pipeline Phase II
Phase II trial of rucaparib maintenance in metastatic endometrial cancer completes follow-up Can a maintenance drug help keep advanced endometrial cancer at bay?
A phase II randomized controlled trial evaluated rucaparib maintenance versus placebo in 79 patients with metastatic/recurrent endometrial c…
A trial testing rucaparib as maintenance therapy for advanced endometrial cancer has finished, but results on whether it delays cancer growt…
CT.gov Mar 30, 2026